IL244709A0 - Methods for diagnosis and treatment of eosinophilic disorders - Google Patents
Methods for diagnosis and treatment of eosinophilic disordersInfo
- Publication number
- IL244709A0 IL244709A0 IL244709A IL24470916A IL244709A0 IL 244709 A0 IL244709 A0 IL 244709A0 IL 244709 A IL244709 A IL 244709A IL 24470916 A IL24470916 A IL 24470916A IL 244709 A0 IL244709 A0 IL 244709A0
- Authority
- IL
- Israel
- Prior art keywords
- diagnosing
- methods
- eosinophilic disorders
- treating eosinophilic
- treating
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
- C07K16/4291—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6851—Quantitative amplification
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Pathology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361894831P | 2013-10-23 | 2013-10-23 | |
| PCT/US2014/061759 WO2015061441A1 (en) | 2013-10-23 | 2014-10-22 | Methods of diagnosing and treating eosinophilic disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL244709A0 true IL244709A0 (en) | 2016-04-21 |
Family
ID=52993499
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL244709A IL244709A0 (en) | 2013-10-23 | 2016-03-22 | Methods for diagnosis and treatment of eosinophilic disorders |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US20170067108A1 (https=) |
| EP (1) | EP3060685B1 (https=) |
| JP (2) | JP6715767B2 (https=) |
| KR (1) | KR20160068802A (https=) |
| CN (1) | CN105849280B (https=) |
| AR (1) | AR098155A1 (https=) |
| AU (1) | AU2014340129A1 (https=) |
| BR (1) | BR112016008694A2 (https=) |
| CA (1) | CA2924873A1 (https=) |
| IL (1) | IL244709A0 (https=) |
| MX (1) | MX2016005159A (https=) |
| RU (1) | RU2016119425A (https=) |
| SG (1) | SG11201603127WA (https=) |
| WO (1) | WO2015061441A1 (https=) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI634900B (zh) | 2013-07-11 | 2018-09-11 | 再生元醫藥公司 | 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法 |
| SG11201605580RA (en) | 2014-01-10 | 2016-10-28 | Anaptysbio Inc | Antibodies directed against interleukin-33 (il-33) |
| TWI705976B (zh) | 2014-11-10 | 2020-10-01 | 美商建南德克公司 | 抗介白素-33抗體及其用途 |
| CN107109494B (zh) | 2014-11-10 | 2023-10-27 | 豪夫迈·罗氏有限公司 | Il-33介导型疾病的治疗方法和诊断方法 |
| EA201890891A1 (ru) * | 2015-10-06 | 2018-09-28 | Ридженерон Фармасьютикалз, Инк. | Биомаркеры, связанные с заболеваниями, опосредованными интерлейкином-33 (ил-33), и их применение |
| KR102460040B1 (ko) | 2016-04-27 | 2022-11-01 | 애브비 인코포레이티드 | 항-il-13 항체를 이용한 il-13 활성이 유해한 질환의 치료 방법 |
| WO2017197360A1 (en) * | 2016-05-13 | 2017-11-16 | The Regents Of The University Of California | Airway mucus impaction |
| PE20191548A1 (es) | 2017-02-10 | 2019-10-24 | Genentech Inc | Anticuerpos contra triptasa, composiciones de estos y usos de estos |
| KR20240070727A (ko) * | 2017-04-12 | 2024-05-21 | 암젠 인크 | 항-tslp 항체를 이용한 천식의 치료 |
| SG11201909048TA (en) | 2017-04-21 | 2019-11-28 | Genentech Inc | Use of klk5 antagonists for treatment of a disease |
| WO2018200473A1 (en) * | 2017-04-24 | 2018-11-01 | The General Hospital Corporation | Detection and targeting of tumor-promoting neutrophils cross-reference to related applications |
| US10676522B2 (en) * | 2017-05-05 | 2020-06-09 | Novartis Ag | Methods of selectively treating asthma using IL-17 antagonists |
| KR20200016232A (ko) | 2017-05-05 | 2020-02-14 | 알라코스 인크. | 알레르기성 안구 질환을 치료하기 위한 방법 및 조성물 |
| IL315556A (en) * | 2017-08-04 | 2024-11-01 | Regeneron Pharma | Methods for treating active eosinophilic esophagitis |
| GB201718667D0 (en) * | 2017-11-10 | 2017-12-27 | Mologic Ltd | Monitoring inflammation status |
| AU2019218128A1 (en) | 2018-02-09 | 2020-09-17 | Genentech, Inc. | Therapeutic and diagnostic methods for mast cell-mediated inflammatory diseases |
| US20210361693A1 (en) * | 2018-02-09 | 2021-11-25 | Empirico Inc. | Process to inhibit or eliminate eosinophilic diseases of the airway and related conditions |
| US20200040103A1 (en) | 2018-03-14 | 2020-02-06 | Genentech, Inc. | Anti-klk5 antibodies and methods of use |
| BR112020022236A2 (pt) * | 2018-05-04 | 2021-02-02 | Allakos Inc. | métodos e composições para tratamento de urticária crônica |
| CN108949954A (zh) * | 2018-07-03 | 2018-12-07 | 张罗 | 用于检测慢性鼻窦炎伴鼻息肉亚型的试剂盒及alox15基因作为生物标志物的应用 |
| WO2020007227A1 (zh) * | 2018-07-03 | 2020-01-09 | 首都医科大学附属北京同仁医院 | 检测慢性鼻窦炎伴鼻息肉亚型的方法和试剂盒及alox15基因作为生物标志物的应用 |
| CN108913764A (zh) * | 2018-07-03 | 2018-11-30 | 张罗 | 检测鼻腔脱落细胞中alox15基因表达量的方法及应用 |
| CN113195738B (zh) * | 2018-08-04 | 2025-01-28 | 帝国理工学院创新有限公司 | 识别患有川崎病的受试者的方法 |
| WO2020092015A1 (en) | 2018-11-02 | 2020-05-07 | University Of Rochester | Therapeutic mitigation of epithelial infection |
| WO2020117840A2 (en) * | 2018-12-05 | 2020-06-11 | Empirico Inc. | Process to inhibit or eliminate eosinophilic diseases of the airway and related conditions |
| EP3911632A1 (en) | 2019-01-15 | 2021-11-24 | Empirico Inc. | Prodrugs of alox-15 inhibitors and methods of using the same |
| WO2020160516A1 (en) * | 2019-01-31 | 2020-08-06 | The Regents Of The University Of California | Materials and methods for identifying and treating eosinophilic disorders |
| US20220259656A1 (en) * | 2019-05-03 | 2022-08-18 | Merck Sharp & Dohme Corp. | Blood biomarker and genetic markers associated with response to crth2 receptor antagonists |
| US12233177B2 (en) | 2019-09-16 | 2025-02-25 | Amgen Inc. | Method for external sterilization of drug delivery device |
| PE20221906A1 (es) | 2019-09-18 | 2022-12-23 | Genentech Inc | Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecificos anti-klk5/klk7 y metodos de uso |
| AU2021236306A1 (en) | 2020-03-13 | 2022-09-15 | Genentech, Inc. | Anti-interleukin-33 antibodies and uses thereof |
| JP7572835B2 (ja) | 2020-10-26 | 2024-10-24 | 株式会社三井ハイテック | 分割型積層鉄心及び分割型積層鉄心の製造方法 |
| CA3230302A1 (en) * | 2021-09-30 | 2023-04-06 | Regeneron Pharmaceuticals, Inc. | Reticulocalbin-3 (rcn3) variants and treatment of asthma with interleukin-4 receptor alpha (il4r) antagonists |
| US20230152330A1 (en) * | 2021-11-17 | 2023-05-18 | AmMax Bio, Inc. | Detection and treatment of idiopathic pulmonary fibrosis |
| AU2023259352A1 (en) * | 2022-04-26 | 2024-10-10 | Regeneron Pharmaceuticals, Inc. | Transcriptome analysis for treating inflammation |
| IL317083A (en) | 2022-06-17 | 2025-01-01 | Apogee Biologics Inc | Antibodies that bind interleukin 13 and methods of use |
| DE102023114008B3 (de) | 2023-05-26 | 2024-09-12 | Precision For Medicine Gmbh | CRTH2 (PTGDR2) als epigenetischer Marker zur Identifizierung von Immunzellen |
| KR20250017928A (ko) * | 2023-07-28 | 2025-02-04 | 재단법인 아산사회복지재단 | 객담 단백체를 이용한 생물학적 제제에 대한 천식 치료 반응성 예측을 위한 바이오마커 및 이의 용도 |
| WO2025032112A1 (en) * | 2023-08-08 | 2025-02-13 | Institut National de la Santé et de la Recherche Médicale | Methods for the treatment of type 2-mediated diseases |
| WO2025117848A1 (en) | 2023-12-01 | 2025-06-05 | Genentech, Inc. | Low-viscosity variants of antibodies |
| WO2025147585A1 (en) * | 2024-01-03 | 2025-07-10 | The Regents Of The University Of California | Use of epigenetic and genomic biomarkers for assessing drug response to type 2 inflammatory diseases |
Family Cites Families (115)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4018653A (en) | 1971-10-29 | 1977-04-19 | U.S. Packaging Corporation | Instrument for the detection of Neisseria gonorrhoeae without culture |
| US4016043A (en) | 1975-09-04 | 1977-04-05 | Akzona Incorporated | Enzymatic immunological method for the determination of antigens and antibodies |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4318980A (en) | 1978-04-10 | 1982-03-09 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a cycling reactant as label |
| US4424279A (en) | 1982-08-12 | 1984-01-03 | Quidel | Rapid plunger immunoassay method and apparatus |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| US5700637A (en) | 1988-05-03 | 1997-12-23 | Isis Innovation Limited | Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays |
| EP0368684B2 (en) | 1988-11-11 | 2004-09-29 | Medical Research Council | Cloning immunoglobulin variable domain sequences. |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| CA2405246A1 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with alterred binding properties |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| WO1993006217A1 (en) | 1991-09-19 | 1993-04-01 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES |
| FI941572L (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| AU675929B2 (en) | 1992-02-06 | 1997-02-27 | Curis, Inc. | Biosynthetic binding protein for cancer marker |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| US5807522A (en) | 1994-06-17 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for fabricating microarrays of biological samples |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| ATE296315T1 (de) | 1997-06-24 | 2005-06-15 | Genentech Inc | Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| WO1999022764A1 (en) | 1997-10-31 | 1999-05-14 | Genentech, Inc. | Methods and compositions comprising glycoprotein glycoforms |
| US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
| ES2375931T3 (es) | 1997-12-05 | 2012-03-07 | The Scripps Research Institute | Humanización de anticuerpo murino. |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| ES2292236T3 (es) | 1998-04-02 | 2008-03-01 | Genentech, Inc. | Variantes de anticuerpos y sus fragmentos. |
| ES2434961T5 (es) | 1998-04-20 | 2018-01-18 | Roche Glycart Ag | Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo |
| HU230769B1 (hu) | 1999-01-15 | 2018-03-28 | Genentech Inc. | Módosított effektor-funkciójú polipeptid-változatok |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| EP1176195B1 (en) | 1999-04-09 | 2013-05-22 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| CN100427603C (zh) | 1999-10-04 | 2008-10-22 | 麦迪卡格公司 | 调控外源基因转录的方法 |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| CA2388245C (en) | 1999-10-19 | 2012-01-10 | Kyowa Kirin Co., Ltd. | The use of serum-free adapted rat cells for producing heterologous polypeptides |
| AU784983B2 (en) | 1999-12-15 | 2006-08-17 | Genentech Inc. | Shotgun scanning, a combinatorial method for mapping functional protein epitopes |
| WO2001075166A2 (en) | 2000-03-31 | 2001-10-11 | Genentech, Inc. | Compositions and methods for detecting and quantifying gene expression |
| CN101289511A (zh) | 2000-04-11 | 2008-10-22 | 杰南技术公司 | 多价抗体及其应用 |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| ES2639222T5 (es) | 2000-10-06 | 2023-11-24 | Kyowa Kirin Co Ltd | Células que producen unas composiciones de anticuerpo |
| US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| CN1487996B (zh) | 2000-11-30 | 2010-06-16 | 米德列斯公司 | 用于生产人类抗体的转基因转染色体啮齿动物 |
| EP2180044A1 (en) | 2001-08-03 | 2010-04-28 | GlycArt Biotechnology AG | Antibody glycosylation variants having increased anti-body-dependent cellular cytotoxicity |
| HUP0600342A3 (en) | 2001-10-25 | 2011-03-28 | Genentech Inc | Glycoprotein compositions |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| CA2481920A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Antibody composition-containing medicament |
| US20040132140A1 (en) | 2002-04-09 | 2004-07-08 | Kyowa Hakko Kogyo Co., Ltd. | Production process for antibody composition |
| US20040259150A1 (en) | 2002-04-09 | 2004-12-23 | Kyowa Hakko Kogyo Co., Ltd. | Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa |
| EA200401325A1 (ru) | 2002-04-09 | 2005-04-28 | Киова Хакко Когио Ко., Лтд. | Клетки с модифицированным геномом |
| ATE503829T1 (de) | 2002-04-09 | 2011-04-15 | Kyowa Hakko Kirin Co Ltd | Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins |
| JP4832719B2 (ja) | 2002-04-09 | 2011-12-07 | 協和発酵キリン株式会社 | ＦｃγＲＩＩＩａ多型患者に適応する抗体組成物含有医薬 |
| EP1513879B1 (en) | 2002-06-03 | 2018-08-22 | Genentech, Inc. | Synthetic antibody phage libraries |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| EP3263596A1 (en) | 2002-12-16 | 2018-01-03 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
| CA2510003A1 (en) | 2003-01-16 | 2004-08-05 | Genentech, Inc. | Synthetic antibody phage libraries |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| JP4764818B2 (ja) | 2003-04-11 | 2011-09-07 | メディミューン，エルエルシー | 組換えｉｌ−９抗体およびその使用 |
| GB0407315D0 (en) | 2003-07-15 | 2004-05-05 | Cambridge Antibody Tech | Human antibody molecules |
| US20080241884A1 (en) | 2003-10-08 | 2008-10-02 | Kenya Shitara | Fused Protein Composition |
| JPWO2005035778A1 (ja) | 2003-10-09 | 2006-12-21 | 協和醗酵工業株式会社 | α１，６−フコシルトランスフェラーゼの機能を抑制するＲＮＡを用いた抗体組成物の製造法 |
| ES2672640T3 (es) | 2003-11-05 | 2018-06-15 | Roche Glycart Ag | Moléculas de unión a antígeno con afinidad de unión a receptores Fc y función efectora incrementadas |
| WO2005053742A1 (ja) | 2003-12-04 | 2005-06-16 | Kyowa Hakko Kogyo Co., Ltd. | 抗体組成物を含有する医薬 |
| WO2005093092A2 (en) * | 2004-03-26 | 2005-10-06 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 44 (gpr44) |
| CN1961003B (zh) | 2004-03-31 | 2013-03-27 | 健泰科生物技术公司 | 人源化抗TGF-β抗体 |
| US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
| KR100891620B1 (ko) | 2004-04-13 | 2009-04-02 | 에프. 호프만-라 로슈 아게 | 항-ｐ-셀렉틴 항체 |
| WO2005116088A2 (en) * | 2004-05-25 | 2005-12-08 | The Johns Hopkins University | Methods and compositions for treating diseases and disorders associated with siglec-8 expressing cells |
| AR049390A1 (es) | 2004-06-09 | 2006-07-26 | Wyeth Corp | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
| US20070048785A1 (en) | 2004-06-09 | 2007-03-01 | Lin Laura L | Anti-IL-13 antibodies and complexes |
| US7501121B2 (en) | 2004-06-17 | 2009-03-10 | Wyeth | IL-13 binding agents |
| TWI307630B (en) | 2004-07-01 | 2009-03-21 | Glaxo Group Ltd | Immunoglobulins |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| KR101270829B1 (ko) | 2004-09-23 | 2013-06-07 | 제넨테크, 인크. | 시스테인 유전자조작 항체 및 접합체 |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| AU2006296399B2 (en) | 2005-09-30 | 2011-01-20 | Medimmune Limited | Interleukin-13 antibody composition |
| ATE514793T1 (de) | 2005-09-30 | 2011-07-15 | Centocor Ortho Biotech Inc | Zusammensetzungen und verfahren für il13- biomarker |
| RU2421464C2 (ru) | 2005-10-21 | 2011-06-20 | Новартис Аг | Человеческие антитела к il-13 и их терапевтическое применение |
| EP1957531B1 (en) | 2005-11-07 | 2016-04-13 | Genentech, Inc. | Binding polypeptides with diversified and consensus vh/vl hypervariable sequences |
| WO2007064919A2 (en) | 2005-12-02 | 2007-06-07 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
| GB0600488D0 (en) | 2006-01-11 | 2006-02-22 | Glaxo Group Ltd | Immunoglobulins |
| MX2008008968A (es) | 2006-01-11 | 2008-09-10 | Aerovance Inc | Metodos y composiciones para tratar asma en primates humanos y no humanos. |
| JP2009536527A (ja) | 2006-05-09 | 2009-10-15 | ジェネンテック・インコーポレーテッド | 最適化されたスキャフォールドを備えた結合ポリペプチド |
| WO2008027236A2 (en) | 2006-08-30 | 2008-03-06 | Genentech, Inc. | Multispecific antibodies |
| CA2914170C (en) | 2006-09-08 | 2018-10-30 | Abbvie Bahamas Ltd. | Interleukin-13 binding proteins |
| US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
| CA2674608A1 (en) | 2007-01-09 | 2008-07-17 | Wyeth | Anti-il-13 antibody formulations and uses thereof |
| WO2008086043A2 (en) | 2007-01-10 | 2008-07-17 | Wyeth | Methods and compositions for assessment and treatment of asthma |
| WO2008091814A2 (en) * | 2007-01-22 | 2008-07-31 | Wyeth | Assessment of asthma and allergen-dependent gene expression |
| PT2132230E (pt) | 2007-03-22 | 2014-07-17 | Genentech Inc | Anticorpos apoptóticos anti-ige que se ligam ao ige ligado a membrana |
| JP2010526088A (ja) | 2007-04-30 | 2010-07-29 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 抗ｉｌ−５抗体を投与するための方法 |
| CN100592373C (zh) | 2007-05-25 | 2010-02-24 | 群康科技(深圳)有限公司 | 液晶显示面板驱动装置及其驱动方法 |
| EP2178547A4 (en) | 2007-07-11 | 2011-02-16 | Aerovance Inc | PHARMACEUTICAL POLYPEPTIDE DRY POWDER AEROSOL FORMULATION AND MANUFACTURING METHOD |
| ES2563027T3 (es) | 2008-01-07 | 2016-03-10 | Amgen Inc. | Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática |
| EP2631302A3 (en) * | 2008-03-31 | 2014-01-08 | Genentech, Inc. | Compositions and methods for treating and diagnosing asthma |
| FR2944448B1 (fr) | 2008-12-23 | 2012-01-13 | Adocia | Composition pharmaceutique stable comprenant au moins un anticorps monodonal et au moins un polysacharide amphiphile comprenant des substituants derives d'alcools hydrofobes ou d'amines hydrophobes. |
| TWI732259B (zh) | 2010-12-16 | 2021-07-01 | 美商建南德克公司 | 關於th2抑制作用之診斷及治療 |
| KR20140119777A (ko) | 2012-01-31 | 2014-10-10 | 제넨테크, 인크. | 항-ig-e m1'' 항체 및 그의 사용 방법 |
| EP3725892A1 (en) * | 2012-03-27 | 2020-10-21 | F. Hoffmann-La Roche AG | Methods of prognosing, diagnosing and treating idiopathic pulmonary fibrosis |
-
2014
- 2014-10-22 SG SG11201603127WA patent/SG11201603127WA/en unknown
- 2014-10-22 BR BR112016008694A patent/BR112016008694A2/pt not_active IP Right Cessation
- 2014-10-22 JP JP2016526089A patent/JP6715767B2/ja not_active Expired - Fee Related
- 2014-10-22 AR ARP140103970A patent/AR098155A1/es unknown
- 2014-10-22 WO PCT/US2014/061759 patent/WO2015061441A1/en not_active Ceased
- 2014-10-22 EP EP14856518.7A patent/EP3060685B1/en not_active Not-in-force
- 2014-10-22 CA CA2924873A patent/CA2924873A1/en not_active Abandoned
- 2014-10-22 CN CN201480070162.0A patent/CN105849280B/zh not_active Expired - Fee Related
- 2014-10-22 RU RU2016119425A patent/RU2016119425A/ru not_active Application Discontinuation
- 2014-10-22 MX MX2016005159A patent/MX2016005159A/es unknown
- 2014-10-22 AU AU2014340129A patent/AU2014340129A1/en not_active Abandoned
- 2014-10-22 KR KR1020167010399A patent/KR20160068802A/ko not_active Withdrawn
-
2016
- 2016-03-22 IL IL244709A patent/IL244709A0/en unknown
- 2016-04-22 US US15/136,677 patent/US20170067108A1/en not_active Abandoned
-
2018
- 2018-10-09 US US16/155,706 patent/US20190024178A1/en not_active Abandoned
-
2019
- 2019-11-01 US US16/671,903 patent/US20200165679A1/en not_active Abandoned
-
2020
- 2020-06-08 JP JP2020099159A patent/JP2020178692A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3060685B1 (en) | 2019-05-01 |
| JP6715767B2 (ja) | 2020-07-01 |
| US20190024178A1 (en) | 2019-01-24 |
| AU2014340129A1 (en) | 2016-05-26 |
| RU2016119425A (ru) | 2017-11-28 |
| CA2924873A1 (en) | 2015-04-30 |
| CN105849280A (zh) | 2016-08-10 |
| MX2016005159A (es) | 2016-07-05 |
| KR20160068802A (ko) | 2016-06-15 |
| EP3060685A1 (en) | 2016-08-31 |
| US20170067108A1 (en) | 2017-03-09 |
| JP2020178692A (ja) | 2020-11-05 |
| EP3060685A4 (en) | 2017-10-18 |
| AR098155A1 (es) | 2016-05-04 |
| JP2017501680A (ja) | 2017-01-19 |
| US20200165679A1 (en) | 2020-05-28 |
| BR112016008694A2 (pt) | 2017-10-03 |
| SG11201603127WA (en) | 2016-05-30 |
| CN105849280B (zh) | 2020-11-06 |
| WO2015061441A1 (en) | 2015-04-30 |
| RU2016119425A3 (https=) | 2018-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL244709A0 (en) | Methods for diagnosis and treatment of eosinophilic disorders | |
| IL273688A (en) | Evaluation and treatment of bradykinin-mediated disorders | |
| PL3046470T3 (pl) | Diagnozowanie i leczenie zaburzeń ruchu | |
| ZA201601024B (en) | Methods and compositions for treating brain diseases | |
| IL241191A0 (en) | Local compositions and methods for treating local disorders | |
| SG11201601412XA (en) | Compositions and methods for the treatment of presbyopia | |
| ZA201602839B (en) | Methods of using interleukin-10 for treating diseases and disorders | |
| EP2983657A4 (en) | TREATMENT OF GASTROINTESTINAL AND OTHER DISEASES | |
| IL239957A0 (en) | Assessment, testing and treatment of pkal mediated disorders | |
| GB201320723D0 (en) | Composition and methods of treatment | |
| EP3068492A4 (en) | Neurodegenerative disorders and methods of treatment and diagnosis thereof | |
| EP2958936A4 (en) | METHOD AND COMPOSITIONS FOR TREATING CORI DISEASE | |
| SG11201507135XA (en) | Methods of maintaining and improving muscle function | |
| EP2986306A4 (en) | METHOD FOR USE OF INTERLEUKIN-10 FOR THE TREATMENT OF ILLNESSES AND SUFFERING | |
| GB201307434D0 (en) | Gate Assembly and Method of Use Thereof | |
| PL2968478T3 (pl) | Kompozycje i sposoby do leczenia karboksyhemoglobinemii | |
| ZA201506705B (en) | Methods of treating dyskinesia and related disorders | |
| IL276431A (en) | Treatment of the brain disorders and related symptoms | |
| SMT201900542T1 (it) | Metodi di trattamento dei disturbi del ciclo dell'urea | |
| SG10201802808SA (en) | Method of treating ocular disorders | |
| EP2968550A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ANGIOGENESIS RELATED DISORDERS | |
| HK1228707A1 (en) | Treating brain disorders and biomarkers related thereto |